Enlivex says 79.2% of patients aged 64+ responded to Allocetra vs 47.6% on placebo at 12 months in Phase IIa knee osteoarthritis trial

Enlivex says 79.2% of patients aged 64+ responded to Allocetra versus 47.6% on placebo at 12 months in its Phase IIa knee osteoarthritis trial.

Detected & updated continuously · Source: Nebula